All news

Charles River buys Frontage bioanalysis units for $470 million

Alpha Vantage · Benzinga · · AI-summarised by FinFlash

Charles River Laboratories will acquire Frontage Holdings' bioanalysis and DMPK operations for $470 million in cash, plus up to $75 million in earnouts. The deal expands Charles River's clinical bioanalysis capabilities, balances its lab testing portfolio and targets the growing global bioanalysis market. William Blair calls it an attractive strategic addition.

Read original source

CRL company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.